Clinical Trial Update: A Randomized Trial of Recombinant Humanized Anti-IL-2 Receptor Antibody (Daclizumab) Versus Antithymocyte Globulin (ATG) to Treat the Cytopenia of Myelodysplastic Syndrome (MDS) [Phase 2]

View source ↗

Summary

A Phase 2 randomized trial comparing daclizumab (anti-IL-2 receptor antibody) versus antithymocyte globulin for cytopenia in myelodysplastic syndrome has comple…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• Thymoglobulin (rabbit anti-thymocyte globulin)
• Zenapax (daclizumab)

Snippet

Sponsor: National Heart, Lung, and Blood Institute (NHLBI) | Conditions: Myelodysplastic Syndromes | Phase 2 | Status: COMPLETED